Curant Health

Belkins
Curant Health is a leading patient-centric, collaborative care organization headquartered in the Atlanta area. At Curant, we focus on transforming the patient journey and providing consistent, improved outcomes through our unique, high-touch approach.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

XERIS PHARMACEUTICALS STRENGTHENS ITS PATENT ESTATE

XERIS PHARMACEUTICALS, INC. | August 20, 2021

news image

Xeris Pharmaceuticals, Inc., a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has recently been granted three new patents relating to its formulation technology platforms. The U.S. Patent and Trademark Office granted U.S. Patent Nos. 10,987,399 and 11,020,403 to Xeris, and the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 to ...

Read More

PHARMACY MARKET

ASTRAZENECA AND R-PHARM SIGN AN AGREEMENT TO COOPERATE ON COVID-19 VACCINE DEVELOPMENT

AstraZeneca | December 22, 2020

news image

The Russian Direct Investment Fund (RDIF, Russia's sovereign abundance reserve), The Gamaleya National Center, AstraZeneca and R-Pharm have consented to an arrangement focused on the turn of events and usage of a clinical exploration program to survey the immunogenicity and security of the consolidated utilization of one of the segments of the Sputnik V immunization created by the Gamaleya Center, and one of the segments of the AZD1222 antibody, created by AstraZeneca and the University of O...

Read More

ACACIA PHARMA COMPLETES DRAWDOWN FROM €25 MILLION LOAN FACILITY FROM COSMO PHARMACEUTICALS TO SUPPORT US LAUNCHES OF BARHEMSYS® AND BYFAVO™

Acacia Pharma Group plc | October 12, 2020

news image

Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosm...

Read More

YELLOWDOG ACCELERATES DRUG DISCOVERY FROM ONE YEAR TO LESS THAN ONE DAY WITH A 162,120 CORE SUPERCOMPUTER, ON-DEMAND

Prnewswire | September 21, 2020

news image

In drug discovery, as with many of the life sciences, data is key. The size of a dataset and the quality of the analyses has a powerful influence on the success of a given drug development programme. There is great potential for the cloud to aid drug discovery, as it offers companies the ability to dynamically scale their research and analyse more data than they would with their on-premise infrastructure. OMass Therapeutics saw an opportunity to accelerate their virtual screening capabilities by...

Read More

BUSINESS INSIGHTS

XERIS PHARMACEUTICALS, INC. | August 20, 2021

news image

XERIS PHARMACEUTICALS STRENGTHENS ITS PATENT ESTATE

Xeris Pharmaceuticals, Inc., a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has recently been granted three new patents relating to its formulation technology platforms. The U.S. Patent and Trademark Office granted U.S. Patent Nos. 10,987,399 and 11,020,403 to Xeris, and the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 to ...

Read More

PHARMACY MARKET

AstraZeneca | December 22, 2020

news image

ASTRAZENECA AND R-PHARM SIGN AN AGREEMENT TO COOPERATE ON COVID-19 VACCINE DEVELOPMENT

The Russian Direct Investment Fund (RDIF, Russia's sovereign abundance reserve), The Gamaleya National Center, AstraZeneca and R-Pharm have consented to an arrangement focused on the turn of events and usage of a clinical exploration program to survey the immunogenicity and security of the consolidated utilization of one of the segments of the Sputnik V immunization created by the Gamaleya Center, and one of the segments of the AZD1222 antibody, created by AstraZeneca and the University of O...

Read More

Acacia Pharma Group plc | October 12, 2020

news image

ACACIA PHARMA COMPLETES DRAWDOWN FROM €25 MILLION LOAN FACILITY FROM COSMO PHARMACEUTICALS TO SUPPORT US LAUNCHES OF BARHEMSYS® AND BYFAVO™

Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosm...

Read More

Prnewswire | September 21, 2020

news image

YELLOWDOG ACCELERATES DRUG DISCOVERY FROM ONE YEAR TO LESS THAN ONE DAY WITH A 162,120 CORE SUPERCOMPUTER, ON-DEMAND

In drug discovery, as with many of the life sciences, data is key. The size of a dataset and the quality of the analyses has a powerful influence on the success of a given drug development programme. There is great potential for the cloud to aid drug discovery, as it offers companies the ability to dynamically scale their research and analyse more data than they would with their on-premise infrastructure. OMass Therapeutics saw an opportunity to accelerate their virtual screening capabilities by...

Read More